Abeona Therapeutics庐 added to Membership of U.S. Small-cap Russell 2000庐 Index and Broad-market Russell 3000庐 Index
Abeona Therapeutics (Nasdaq: ABEO) has been added to both the Russell 2000庐 Index and the Russell 3000庐 Index as part of the indexes' annual reconstitution, effective June 30, 2025. This inclusion follows the recent FDA approval of the company's product ZEVASKYN鈩�.
The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. Membership in these indexes is reviewed annually and maintains for one year.
Abeona Therapeutics (Nasdaq: ABEO) 猫 stata inclusa sia nell'Indice Russell 2000庐 che nell'Indice Russell 3000庐 nell'ambito della ricostituzione annuale degli indici, con effetto dal 30 giugno 2025. Questa inclusione segue la recente approvazione da parte della FDA del prodotto ZEVASKYN鈩� dell'azienda.
Gli indici Russell, che rappresentano un benchmark per circa 10,6 trilioni di dollari in asset, sono ampiamente utilizzati dai gestori di investimenti e dagli investitori istituzionali per fondi indicizzati e strategie di investimento attive. L'appartenenza a questi indici viene rivista annualmente e dura un anno.
Abeona Therapeutics (Nasdaq: ABEO) ha sido a帽adida tanto al 脥ndice Russell 2000庐 como al 脥ndice Russell 3000庐 como parte de la reconstituci贸n anual de los 铆ndices, con vigencia a partir del 30 de junio de 2025. Esta inclusi贸n sigue a la reciente aprobaci贸n por parte de la FDA del producto ZEVASKYN鈩� de la compa帽铆a.
Los 铆ndices Russell, que sirven como referencia para aproximadamente 10,6 billones de d贸lares en activos, son ampliamente utilizados por gestores de inversiones e inversores institucionales para fondos indexados y estrategias de inversi贸n activas. La membres铆a en estos 铆ndices se revisa anualmente y se mantiene por un a帽o.
Abeona Therapeutics (雮橃姢雼�: ABEO)臧� 歆�靾� 鞐半 鞛惮靹膘潣 鞚柬櫂鞙茧 霟厐 2000庐 歆�靾�鞕赌 霟厐 3000庐 歆�靾�鞐� 氇憪 韽暔霅橃棃鞙茧┌, 鞚措姅 2025雲� 6鞗� 30鞚茧秬韯� 氚滍毃霅╇媹雼�. 鞚措矆 韽暔鞚� 須岇偓 鞝滍拡 ZEVASKYN鈩㈧潣 斓滉芳 FDA 鞀轨澑鞐� 霐半ジ 瓴冹瀰雼堧嫟.
霟厐 歆�靾橂姅 鞎� 10.6臁� 雼煬 攴滊鞚� 鞛愳偘鞚� 氩れ箻毵堩伂搿� 靷检溂氅�, 韴瀽 甏�毽瀽鞕赌 旮瓣磤 韴瀽鞛愲摛鞚� 鞚鸽嵄鞀� 韼�霌� 氚� 鞝侁饭鞝� 韴瀽 鞝勲灥鞐� 雱愲Μ 頇滌毄頃╇媹雼�. 鞚� 歆�靾橃潣 甑劚鞗� 鞛愱博鞚� 毵る厔 瓴�韱犽悩氅� 1雲勱皠 鞙犾霅╇媹雼�.
Abeona Therapeutics (Nasdaq : ABEO) a 茅t茅 ajout茅e 脿 la fois au Russell 2000庐 Index et au Russell 3000庐 Index dans le cadre de la reconstitution annuelle des indices, effective 脿 partir du 30 juin 2025. Cette inclusion fait suite 脿 l'approbation r茅cente par la FDA du produit ZEVASKYN鈩� de la soci茅t茅.
Les indices Russell, qui servent de r茅f茅rence pour environ 10,6 billions de dollars d'actifs, sont largement utilis茅s par les gestionnaires d'investissements et les investisseurs institutionnels pour les fonds indiciels et les strat茅gies d'investissement actives. L'appartenance 脿 ces indices est r茅vis茅e chaque ann茅e et est maintenue pendant un an.
Abeona Therapeutics (Nasdaq: ABEO) wurde im Rahmen der j盲hrlichen Neukonstituierung der Indizes sowohl in den Russell 2000庐 Index als auch in den Russell 3000庐 Index aufgenommen, wirksam ab dem 30. Juni 2025. Diese Aufnahme folgt auf die k眉rzliche FDA-Zulassung des Produkts ZEVASKYN鈩� des Unternehmens.
Die Russell-Indizes, die als Benchmark f眉r etwa 10,6 Billionen US-Dollar an Verm枚genswerten dienen, werden von Investmentmanagern und institutionellen Anlegern h盲ufig f眉r Indexfonds und aktive Anlagestrategien genutzt. Die Mitgliedschaft in diesen Indizes wird j盲hrlich 眉berpr眉ft und gilt f眉r ein Jahr.
- None.
- None.
CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000庐 Index and the broad-market Russell 3000庐 Index as part of the reconstitution of the Russell stock indexes, effective at the open of the U.S. equity markets today.
鈥淎beona's addition to the Russell 2000 and 3000 indexes, on the heels of ZEVASKYN鈩�'s FDA approval, represents a pivotal moment for the company,鈥� said Joe Vazzano, Chief Financial Officer of Abeona. 鈥淭his inclusion amplifies our positive momentum as we progress with ZEVASKYN's commercial launch and provides an opportunity to engage with a broader audience of investors.鈥�
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about
Membership in the Russell 3000庐 Index means automatic inclusion in either the large-cap Russell 1000庐 Index or small-cap Russell 2000庐 Index, as well as the appropriate growth and value style indexes. The Russell 3000庐 Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year. For more information on the Russell 2000庐 and Russell 3000庐 Indexes and the Russell U.S. Indexes Reconstitution, visit the 鈥淩ussell Reconstitution鈥� section on the FTSE Russell website.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona鈥檚 ZEVASKYN鈩� (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company鈥檚 fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company鈥檚 development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona鈥檚 novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit .
ZEVASKYNTM, Abeona AssistTM, Abeona Therapeutics庐, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渂elieve,鈥� 鈥渁nticipate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥減otential,鈥� and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN, the therapeutic potential of ZEVASKYN, whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company鈥檚 expectations, continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections from the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company鈥檚 most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics [email protected]
FAQ
What indexes was Abeona Therapeutics (ABEO) added to in June 2025?
How long will Abeona Therapeutics (ABEO) remain in the Russell indexes?
What is the significance of ABEO joining the Russell indexes?
How much in assets are benchmarked against Russell U.S. indexes?
What recent product approval did Abeona Therapeutics receive?
